These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

966 related items for PubMed ID: 19617343

  • 1. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [Abstract] [Full Text] [Related]

  • 2. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
    Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, Amthauer H.
    Neuroendocrinology; 2010 Aug; 91(1):101-9. PubMed ID: 19996582
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC, Beer AJ, Souvatzoglou M, Eiber M, Fürst S, Ziegler SI, Brohl F, Schwaiger M, Scheidhauer K.
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [Abstract] [Full Text] [Related]

  • 5. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I.
    J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
    [Abstract] [Full Text] [Related]

  • 6. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
    Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ.
    J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
    [Abstract] [Full Text] [Related]

  • 7. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
    Schiesser M, Veit-Haibach P, Muller MK, Weber M, Bauerfeind P, Hany T, Clavien PA.
    Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
    [Abstract] [Full Text] [Related]

  • 8. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18.
    Basu D, Siegel BA, McDonald DJ, Nussenbaum B.
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):801-5. PubMed ID: 17709620
    [Abstract] [Full Text] [Related]

  • 9. Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.
    Giesel FL, Kratochwil C, Mehndiratta A, Wulfert S, Moltz JH, Zechmann CM, Kauczor HU, Haberkorn U, Ley S.
    Eur J Radiol; 2012 Oct; 81(10):2820-5. PubMed ID: 22236704
    [Abstract] [Full Text] [Related]

  • 10. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
    Froeling V, Röttgen R, Collettini F, Rothe J, Hamm B, Brenner W, Schreiter N.
    Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
    [Abstract] [Full Text] [Related]

  • 11. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
    Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Bogaerts K, Haustermans K, Nackaerts K, Van Cutsem E, Verslype C, Verbruggen A, Deroose CM.
    Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
    [Abstract] [Full Text] [Related]

  • 12. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, de Klerk JM, Oyen WJ, Meijer S, Hoekstra HJ.
    J Clin Oncol; 2009 Oct 01; 27(28):4774-80. PubMed ID: 19720925
    [Abstract] [Full Text] [Related]

  • 13. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.
    Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E.
    J Nucl Med; 2004 Feb 01; 45(2):272-8. PubMed ID: 14960647
    [Abstract] [Full Text] [Related]

  • 14. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
    Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.
    J Nucl Med; 2017 Mar 01; 58(3):451-457. PubMed ID: 27660147
    [Abstract] [Full Text] [Related]

  • 15. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
    Steffen IG, Mehl S, Heuck F, Elgeti F, Furth C, Amthauer H, Ruf J.
    Clin Nucl Med; 2009 Dec 01; 34(12):869-73. PubMed ID: 20139819
    [Abstract] [Full Text] [Related]

  • 16. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
    Nakamoto Y, Sano K, Ishimori T, Ueda M, Temma T, Saji H, Togashi K.
    Ann Nucl Med; 2015 Jul 01; 29(6):512-8. PubMed ID: 25894056
    [Abstract] [Full Text] [Related]

  • 17. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B.
    J Nucl Med; 2014 Feb 01; 55(2):204-10. PubMed ID: 24379222
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC.
    Invest Radiol; 2013 May 01; 48(5):273-9. PubMed ID: 23493121
    [Abstract] [Full Text] [Related]

  • 19. [Detection of a neuroendocrine differentiated cystic pancreatic lesion by gallium-68-DOTATOC-PET/CT with inconclusive MRI, CT and ultrasound diagnosis].
    Fröling V, Denecke T, Pöllinger A, Schreiter NF.
    Rofo; 2010 Feb 01; 182(2):175-7. PubMed ID: 19998214
    [No Abstract] [Full Text] [Related]

  • 20. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
    Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW.
    J Nucl Med; 2009 Apr 01; 50(4):513-9. PubMed ID: 19289420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.